The Psychedelic Renaissance
After nearly five decades of regulatory prohibition, psychedelic research has experienced a dramatic revival since the early 2000s. What started as a handful of small-scale studies has grown into a global research enterprise involving major universities, well-funded biotech companies, and regulatory agencies — producing some of the most promising results in psychiatric medicine in a generation.
Understanding this research landscape — who is conducting studies, what the findings actually show, and how to critically evaluate the evidence — is essential for anyone seeking accurate information about psychedelics and mental health.
Major Research Institutions
- •Johns Hopkins Center for Psychedelic & Consciousness Research: Founded in 2019 with $17 million in funding. Led landmark psilocybin studies for depression, tobacco addiction, and existential distress. Roland Griffiths' work here defined the modern field.
- •NYU Langone Center for Psychedelic Medicine: Pioneering research on psilocybin for alcohol use disorder and end-of-life anxiety. Phase 2 and 3 trials ongoing.
- •Imperial College London — Centre for Psychedelic Research: The first academic center dedicated to psychedelic research (2019). Produced groundbreaking neuroimaging studies showing how psychedelics affect brain networks.
- •MAPS (Multidisciplinary Association for Psychedelic Studies): Founded in 1986 by Rick Doblin. Led the MDMA-assisted therapy clinical program for PTSD through Phase 3 trials. The most established psychedelic research organization.
- •University of California, Berkeley — Center for the Science of Psychedelics: Focuses on both neuroscience and the humanistic/philosophical dimensions of psychedelic experience.
- •University of Basel (Switzerland): Leading LSD research including microdosing studies and clinical trials for anxiety and depression.
Clinical Trial Pipeline
Several psychedelic compounds are progressing through the FDA's clinical trial process:
Phase 3 / Near Approval
- •MDMA for PTSD (MAPS/Lykos): Completed Phase 3. FDA Breakthrough Therapy designation. Regulatory pathway ongoing.
- •Psilocybin for treatment-resistant depression (COMPASS Pathways): Phase 2b completed. Phase 3 underway. FDA Breakthrough Therapy designation.
- •Psilocybin for major depressive disorder (Usona Institute): Phase 2 completed with strong results. Phase 3 planned.
Phase 2
- •Psilocybin for alcohol use disorder: NYU Phase 2 showed 83% reduction in heavy drinking days.
- •Psilocybin for anorexia nervosa: Multiple trials underway (Johns Hopkins, Imperial College).
- •LSD for anxiety: Phase 2 trials at University of Basel and MindMed.
Earlier Stage / Emerging
- •Psilocybin for OCD, cluster headaches, opioid use disorder
- •DMT (short-acting) for depression — Phase 1/2 (Small Pharma/SPL026)
- •5-MeO-DMT for treatment-resistant depression — early-stage trials
- •Ibogaine for traumatic brain injury — observational studies
Understanding FDA Designations
- •Breakthrough Therapy Designation: The FDA's way of fast-tracking a drug that shows substantial improvement over existing treatments. Both psilocybin (COMPASS Pathways) and MDMA (MAPS) have received this designation. Important: This is not approval — it means the FDA is committed to expedited review.
- •Phase 1: Safety testing in a small group of healthy volunteers. Determines safe dosage range and side effects.
- •Phase 2: Efficacy testing in a larger group of people with the target condition. Determines whether the drug works and identifies optimal dosing.
- •Phase 3: Large-scale efficacy confirmation in diverse populations. Compares to existing treatments or placebo. Required for FDA approval.
- •New Drug Application (NDA): The formal request for FDA marketing approval. Reviewed by an advisory committee. Can be approved, rejected, or require additional data.
How to Read Psychedelic Research
As media coverage of psychedelic research increases, the ability to critically evaluate studies becomes essential. Key considerations:
- •Sample size matters: Many psychedelic studies have small sample sizes (20-100 participants). Results are suggestive but require larger replication studies.
- •The blinding problem: Psychedelic effects are obvious to participants, making true placebo-controlled trials extremely difficult. This "expectancy effect" may inflate results.
- •Selection bias: Trial participants are carefully screened and highly motivated. Results may not generalize to the broader population.
- •Publication bias: Studies with positive results are more likely to be published. We may not be seeing the full picture.
- •Therapy vs. drug: In psychedelic-assisted therapy, participants receive extensive therapeutic support. It's difficult to separate the drug's effects from the therapy's effects.
- •Follow-up duration: Many studies report results at 1-6 months. Long-term durability of effects (1+ years) is less established.
- •Funding sources: Be aware of who funded the study. Industry-funded research can introduce bias, though academic funding also has limitations.
The Neuroscience
Modern neuroimaging has revealed how psychedelics affect the brain:
- •Default Mode Network (DMN) disruption: Psychedelics reduce activity in the DMN — the brain network associated with self-referential thinking, rumination, and the "narrative self." This may explain ego dissolution and the interruption of depressive thought loops.
- •Increased connectivity: Brain regions that don't normally communicate begin exchanging information, potentially enabling novel perspectives and creative insights.
- •Neuroplasticity: Psychedelics promote the growth of new dendrites and synaptic connections, particularly in the prefrontal cortex. This "plasticity window" may explain lasting benefits from single sessions.
- •Entropic brain hypothesis: Robin Carhart-Harris's theory suggests psychedelics increase brain entropy (disorder), temporarily disrupting rigid patterns and allowing for reorganization.